24/7 Market News Snapshot 02 October, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)

October 2, 2025

DENVER, Colo., 02 October, 2025 (www.247marketnews.com) – (Nasdaq:PALI) are discussed in this article.
Palisade Bio, Inc. (Nasdaq:PALI), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases, has experienced a substantial rise in its stock price, currently trading at $1.715, reflecting an increase of 30.92% from the prior session’s close of $1.31. This surge highlights a strong market response, underpinned by a remarkable trading volume of 20.35 million shares, indicative of heightened investor interest and confidence in the company’s pipeline.

Adding to this momentum, Palisade Bio recently announced the successful completion of an underwritten public offering, raising approximately $138 million in gross proceeds. This investment underscores robust approval from a diverse group of prestigious investors, including B Group Capital and Columbia Threadneedle Investments, along with several other leading healthcare investment firms. The CEO, J.D. Finley, emphasized the importance of this support, stating that it not only reinforces the promise of their innovative science but also signals significant potential for their lead candidate, PALI-2108, a first-in-class PDE4 B/D inhibitor aimed at addressing critical unmet needs in inflammatory bowel disease (IBD).

The public offering consisted of 197,154,844 shares priced at $0.70 each, with full exercise of the underwriters’ over-allotment option indicating strong market confidence. This influx of capital will facilitate the acceleration of PALI-2108’s Phase 2 clinical development, enabling the company to expand its research efforts and enhance shareholder value.

Palisade Bio is firmly positioned to continue its commitment towards transforming treatment avenues for patients with autoimmune and inflammatory conditions, focusing on delivering innovative solutions that cater to significant health challenges.

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.